Genome Research Group and ChromoCure Prepare for HHS' $1 Billion ARRA Funds for Research Labs: Grants to Advance Research Nation
20 May 2010 - 10:30PM
Marketwired
ChromoCure, Inc. (Genome Research Group, Inc.) (PINKSHEETS: KKUR)
announced today its planned US Research Grant Centres. This program
is in direct in response to the US Department of Health and Human
Services' (HHS) $1 billion in American Recovery and Reinvestment
Act funds for the construction, repair, and renovation of
biomedical research labs across the country.
U.S. Health and Human Services Secretary Kathleen Sebelius
announced May 14th $1 billion of American Recovery and Reinvestment
Act funds have been awarded to construct, repair and renovate
scientific research laboratories and related facilities across the
country.
The National Institutes of Health (NIH) National Center for
Research Resources (NCRR) administered the grants, which are
expected to create or sustain jobs nationwide and to help foster
scientific advances that may lead to improved human health.
"This unprecedented Recovery Act investment in research facility
construction will not only give our world-class scientists the
modern facilities they need for impact research, it will also help
create and maintain jobs in varied business sectors and in all
regions of our country," said Secretary Sebelius.
This announcement adds further impetus to the worldwide increase
in medical genome research that has emerged since The Mayo Clinic
published its landmark findings confirming aneuploidy as the cause
of cancer in the December 2009 Cancer Cell journal. This
publication has spurred increased worldwide research by a number of
respected research universities and institutions, all of which have
published similar reports in 2010, and is cited to be one of the
contributing factors behind Walgreens' recently announced mail-in
genetic testing kits to be offered at 7,500 of their retail
locations nationwide.
The Company's cancer detection technology is based on the
chromosomal theory of cancer. Research has conclusively and
irrefutably demonstrated aneuploidy a more accurate predictor of
cancer than cytological/histological analysis or genetic
marker-based diagnostics that are the only other methods in
existence today.
The Company's cancer detection system locates and measures
unique genomic characteristics found in 100% of all cancers and
never found in normal cells. The Company's detection technology has
an effective 100% accuracy rate and an effective 100% specificity
therefore making "false positives" and "false negatives"
theoretically impossible.
This announcement, together with the recently announced addition
of Full Spectrum ChromoSomal Scan Capability for Broad Base Cancer
Progression Assessment: Further Enhancing Detection &
Progression Monitoring, the Clinical Testing and Trials for its
landmark ChromoSomal Scanning Technology as applied to cervical
cancer and the Euro Zone launch of its Pathologist Collaborative
Research (PCR) Program in support of the groundbreaking Project
Boveri: Find the Cure Initiative, further establishes the Company's
leading role in the new era of cancer research, detection, and
therapy, as the companies leverage their combined technologies,
research knowledge and industry relationships.
The Company possesses advanced detection and therapeutic
technology and protocols, comprised of ChromoCure's advanced
detection system and GRG's full line of therapeutic protocols and
technology, allowing for the first time real-time progression
monitoring and remission detection -- providing the world's first
cure research fully integrated system for the precise measurement
of treatment and on-demand, real-time cancer progression analysis
to monitor and determine treatment efficacy.
The Company's combined technologies have been validated in
clinical trials and provide the foundation for significant advances
in diagnosis, therapy and cure, and placed the Company at the
forefront of both cancer detection and research. Shareholders can
expect further updates on research and testing collaborations,
laboratory partnerships, and research initiatives.
Management believes these initiatives to be of significant
long-term shareholder value and furthers the Company's transition
to research, technology development, and licensing as a source of
significant long-term and recurring revenues and equity
appreciation.
About Genome Research Group, Inc. (ChromoCure,
Inc.) The Company develops and provides proprietary cancer
detection systems and related therapeutic technologies. The
Company's proprietary cancer detection system locates and measures
unique genomic characteristic found in 100% of all cancers and
never found in normal cells. The Company's detection technology has
a proven and effective accuracy of 100% for all cancers at all
stages. The Company's proprietary Therapeutic Modeling Protocols
provide statistical modeling and prediction tools for the
measurement and monitoring of cancer progression and remission. The
Company also applies its technology and knowledge to cancer cure
and therapeutics research.
The Company owns proprietary cancer detection systems and
related therapeutic technologies and proprietary techniques for
non-toxic and non-invasive cancer therapy utilizing hypothermic
modulation and resonance. The Company's proprietary CS200
Chromosomal Scanner has been proven accurate and efficient in the
measurement of the unique genomic characteristic found in 100% of
all cancers and never found in normal cells. The Company's
detection technology has an effective accuracy of 100% for all
cancers at all stages. GRG's advanced Therapeutic Modeling and
Treatment Protocols, combined with its industry and medical
research collaborations, validate its leadership role in Cancer
Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that are forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated on the Company's website "investors" section
by reference) and should be read before any investment
decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024